Biohaven Ltd. (NYSE:BHVN) has announced major breakthroughs with its novel precision immunology therapies, BHV-1400 and ...

The global IgA nephropathy market is poised for substantial growth, with sales projected to increase from USD 46,821.7 million in 2025 to a remarkable USD 99,655.4 million by 2035. According to the ...

Just over 4,200 people could be set to benefit after Sparsentan (also known as Filspari and made by Vifor Pharma) was recommended in final draft guidance as an option for treating primary ...

The Ashland Middle School teacher, at 37, discovered her symptoms of rashes and bloody urine had a name: IgA Nephropathy. It’s also called Berger disease. The condition is a rare form of chronic ...

For more information, visit travere.com. About IgA Nephropathy (IgAN) IgAN, also called Berger’s disease, is a rare progressive kidney disease characterized by the buildup of immunoglobulin A (IgA), a ...

IgA nephropathy, also known as Berger disease, is a chronic kidney disorder characterized by the deposition of immunoglobulin A (IgA) antibodies in the glomeruli—the tiny filtering units within ...

For more information about CSL Vifor visit, cslvifor.com. About IgA Nephropathy (IgAN) IgAN, also called Berger’s disease, is a rare progressive kidney disease characterized by the buildup of ...

Learn more about the IgA nephropathy Berger's disease treatment @ IgA Nephropathy Disease Treatment Market FILSPARI is the first and only once-daily oral therapy for IgA nephropathy that does not ...

Learn more about the IgA nephropathy Berger's disease treatment @ IgA Nephropathy Disease Treatment Market FILSPARI is the first and only once-daily oral therapy for IgA nephropathy that does not ...